MTOR and cancer: Furthermore, we demonstrate that simultaneous inhibition of class I PI3K and mTOR may offer a better therapeutic approach for canine cancer therapy than the concomitant treatment of the PI3K pathway in combination with conventional cancer cytotoxic drugs.